Other
SkylineDx
is a biotechnology company that provides gene signature-based diagnostic testing services for cancer... Read moreSkylineDx
is a biotechnology company that provides gene signature-based diagnostic testing services for cancer... Read moreNews
Apr 04, 2025
FinanzNachrichten
SkylineDx: SkylineDx Presents Landmark Study on Merlin CP-GEP beyond SLNB prediction: Transforming Melanoma Risk Assessment
Mar 28, 2025
FinanzNachrichten
SkylineDx: SkylineDx presents landmark findings from the largest prospective multicenter melanoma GEP trial at SSO 2025
Mar 12, 2025
FinanzNachrichten
SkylineDx: SKYLINEDX ANNOUNCES NEW STUDY DEMONSTRATING ENHANCED RISK STRATIFICATION FOR SENTINEL LYMPH NODE BIOPSY IN HEAD AND NECK MELANOMA USING THE ADVANCED MERLIN CP-GEP TEST
Mar 03, 2025
Medical Device Network
SkylineDx: SkylineDx study highlights value in combined myeloma diagnostic approach
Feb 28, 2025
FinanzNachrichten
SkylineDx: SKYLINEDX ANNOUNCES NEW PUBLICATION ON SKY92 GENE EXPRESSION PROFILING TEST in DEFINING ULTRA-HIGH-RISK MULTIPLE MYELOMA
Dec 07, 2024
FinanzNachrichten
SkylineDx: SkylineDx: New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients
Oct 24, 2024
FinanzNachrichten
SkylineDx: SkylineDx: Independent meta-analyses by Melanoma Institute of Australia on CP-GEP model in Melanoma Care
Oct 14, 2024
Medical Device Network
SkylineDx: SkylineDx reports data from melanoma genomic assay in US trial
May 30, 2024
FinanzNachrichten
SkylineDx: SkylineDx's Merlin Assay stratifies Stage I/II cutaneous melanoma beyond SLNB for recurrence
Apr 05, 2024
FinanzNachrichten
SkylineDx: SkylineDx: Independent European data on CP-GEP model in Stratifying Melanoma Patients for Long Term Survival
SkylineDx Competitors
1
2
3
4
5
6
7
8
9
10